Şebnem Emine Parspur
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Şebnem Emine Parspur has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Feride Marım
Department of Chest Diseases, Faculty of Medicine, Kutahya Health Sciences University, Kütahya, Türkiye
2 shared publications - İlKnur Kaya
Department of Chest Diseases, Faculty of Medicine, Kutahya Health Sciences University, Kütahya, Türkiye
2 shared publications - Ümran Erbay
Department of Chest Diseases, Faculty of Medicine, Kutahya Health Sciences University, Kütahya, Türkiye
2 shared publications - Deniz Uysal
Yalova Eğitim ve Araştırma Hastanesi
1 shared publication Feride Marim
Department of Chest Diseases, Kutahya Health Sciences University Faculty of Medicine, Kütahya, Turkey
1 shared publication- Furkan Tan1 shared publication
Latest Publications
- 20 August 2026
- Published by MediHealth Academy in Journal of Pulmonology and Intensive Care
- Vol. 4 (3) , 73-78
The relationship between the severity of COVID-19 pneumonia and ABO blood groups
Aims: It is known that the distribution of ABO blood groups creates significant differences in viral infections and that blood group type can also be used as a biomarker to predict the risk of SARS-CoV-2 infection. In this study, we aimed to investigate the relationship between disease severity and blood groups in patients diagnosed with COVID-19 pneumonia. Methods: Designed as a retrospective cohort study, our study included patients who were admitted to the Pulmonology Department of Kütahya Health Sciences University Evliya Çelebi Training and Research Hospital for inpatient treatment with a diagnosis of COVID-19 pneumonia between 31.03.2020 and 30.09.20 and sociodemographic characteristics, blood group, Rh status, admission information, and CT findings were recorded from electronic patient records. Blood group characteristics were examined in the categorization based on the radiologically defined severity classification of COVID-19 pneumonia. Results: The study group consisted of 93 men (47.2%) and 104 women (52.8%). Regarding blood type distribution, 50 (25.4%) patients had type 0, 105 (53.3%) had type A, 26 (13.2%) had type B, and 16 (8.1%) had type AB. The blood group distribution according to the Rh factor was 25 (12.7%) Rh (-) and 172 (87.3%) Rh (+). No statistically significant difference was found in the distribution of COVID-19 pneumonia severity on chest computed tomography (CT) based on blood groups (p=0.200). No statistically significant difference was found in the relationship between COVID-19 pneumonia severity on chest CT and the Rh factor (p=0.283). On the other hand, when the relationship between the Rh factor and COVID-19 severity was examined, it was found that patients in the Rh (-) group had a longer intensive care unit (ICU) stay (p=0.001), a higher rate of high-flow oxygen requirement during follow-up (p=0.03), and a higher mortality rate (p=0.02) compared to the Rh (+) group. Conclusion: We have determined that there is no association between ABO blood group distribution characteristics and the severity of COVID-19 pneumonia, but there may be a prognostic association between the Rh factor and the severity of COVID-19.
- 20 August 2026
- Published by MediHealth Academy in Journal of Pulmonology and Intensive Care
- Vol. 4 (3) , 73-78
The relationship between the severity of COVID-19 pneumonia and ABO blood groups
Aims: It is known that the distribution of ABO blood groups creates significant differences in viral infections and that blood group type can also be used as a biomarker to predict the risk of SARS-CoV-2 infection. In this study, we aimed to investigate the relationship between disease severity and blood groups in patients diagnosed with COVID-19 pneumonia. Methods: Designed as a retrospective cohort study, our study included patients who were admitted to the Pulmonology Department of Kütahya Health Sciences University Evliya Çelebi Training and Research Hospital for inpatient treatment with a diagnosis of COVID-19 pneumonia between 31.03.2020 and 30.09.20 and sociodemographic characteristics, blood group, Rh status, admission information, and CT findings were recorded from electronic patient records. Blood group characteristics were examined in the categorization based on the radiologically defined severity classification of COVID-19 pneumonia. Results: The study group consisted of 93 men (47.2%) and 104 women (52.8%). Regarding blood type distribution, 50 (25.4%) patients had type 0, 105 (53.3%) had type A, 26 (13.2%) had type B, and 16 (8.1%) had type AB. The blood group distribution according to the Rh factor was 25 (12.7%) Rh (-) and 172 (87.3%) Rh (+). No statistically significant difference was found in the distribution of COVID-19 pneumonia severity on chest computed tomography (CT) based on blood groups (p=0.200). No statistically significant difference was found in the relationship between COVID-19 pneumonia severity on chest CT and the Rh factor (p=0.283). On the other hand, when the relationship between the Rh factor and COVID-19 severity was examined, it was found that patients in the Rh (-) group had a longer intensive care unit (ICU) stay (p=0.001), a higher rate of high-flow oxygen requirement during follow-up (p=0.03), and a higher mortality rate (p=0.02) compared to the Rh (+) group. Conclusion: We have determined that there is no association between ABO blood group distribution characteristics and the severity of COVID-19 pneumonia, but there may be a prognostic association between the Rh factor and the severity of COVID-19.
- Open Access
- 5 August 2026
- Published by Georg Thieme Verlag KG in World Journal of Nuclear Medicine
- Vol. 25 (03) , 250-254
Evaluation of the Systemic Immune-Inflammation Index, Neutrophil-to-Lymphocyte Ratio, and Platelet-to-Lymphocyte Ratio in Patients Diagnosed with Lung Cancer by Bronchoscopy in Relation to Disease Stage and PET/CT SUVmax
Systemic inflammation in lung cancer is closely associated with tumor progression and prognosis. Hematological parameters such as the systemic immune-inflammation index (SII), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) are readily available, low-cost biomarkers. This study aimed to evaluate the associations of SII, NLR, and PLR with disease stage and the maximum standardized uptake value (SUVmax) measured by 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) in patients with lung cancer diagnosed by bronchoscopy. This retrospective study included 184 of 357 patients who underwent fiberoptic bronchoscopy at the Department of Respiratory Medicine, Kütahya Health Sciences University, between January 2023 and March 2025 and had complete staging data. Demographic characteristics, histopathological diagnoses, 18F-FDG PET/CT SUVmax values, and SII, NLR, and PLR values calculated from complete blood count parameters were recorded. A total of 184 patients were included; 172 (93.5%) were male and 12 (6.5%) were female, and the mean age was 67.9 ± 8.4 years. The most common histopathological diagnosis was non-small cell lung cancer (NSCLC), accounting for 84.8% of cases. No significant associations were found between SII, NLR, or PLR and disease stage or SUVmax. NLR showed a statistically significant but very weak positive correlation with stage IV NSCLC (r = 0.198, p = 0.013), indicating limited explanatory value. The inflammatory indices were not significantly associated with disease stage or 18F-FDG PET/CT SUVmax. Although NLR showed a statistically significant positive correlation with stage IV NSCLC, the effect size was very small and should not be interpreted as evidence of meaningful staging utility. Larger prospective studies are needed to determine whether readily available hematological indices such as SII, NLR, and PLR provide complementary value in prognostic or multimarker models in lung cancer.
- 5 August 2026
- Published by Georg Thieme Verlag KG in World Journal of Nuclear Medicine
- Vol. 25 (03) , 250-254
Open AccessEvaluation of the Systemic Immune-Inflammation Index, Neutrophil-to-Lymphocyte Ratio, and Platelet-to-Lymphocyte Ratio in Patients Diagnosed with Lung Cancer by Bronchoscopy in Relation to Disease Stage and PET/CT SUVmax
Systemic inflammation in lung cancer is closely associated with tumor progression and prognosis. Hematological parameters such as the systemic immune-inflammation index (SII), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) are readily available, low-cost biomarkers. This study aimed to evaluate the associations of SII, NLR, and PLR with disease stage and the maximum standardized uptake value (SUVmax) measured by 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) in patients with lung cancer diagnosed by bronchoscopy. This retrospective study included 184 of 357 patients who underwent fiberoptic bronchoscopy at the Department of Respiratory Medicine, Kütahya Health Sciences University, between January 2023 and March 2025 and had complete staging data. Demographic characteristics, histopathological diagnoses, 18F-FDG PET/CT SUVmax values, and SII, NLR, and PLR values calculated from complete blood count parameters were recorded. A total of 184 patients were included; 172 (93.5%) were male and 12 (6.5%) were female, and the mean age was 67.9 ± 8.4 years. The most common histopathological diagnosis was non-small cell lung cancer (NSCLC), accounting for 84.8% of cases. No significant associations were found between SII, NLR, or PLR and disease stage or SUVmax. NLR showed a statistically significant but very weak positive correlation with stage IV NSCLC (r = 0.198, p = 0.013), indicating limited explanatory value. The inflammatory indices were not significantly associated with disease stage or 18F-FDG PET/CT SUVmax. Although NLR showed a statistically significant positive correlation with stage IV NSCLC, the effect size was very small and should not be interpreted as evidence of meaningful staging utility. Larger prospective studies are needed to determine whether readily available hematological indices such as SII, NLR, and PLR provide complementary value in prognostic or multimarker models in lung cancer.
- Open Access
- 1 May 2025
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 20, 1457-1463
Are Smart Watches Really Smart? Comparison of Blood Oxygen Saturation Values Measured by Smart Watch, Pulse Oximetry and Arterial Blood Gases in Patients with Chronic Obstructive Pulmonary Diseases
Objective: Oxygen saturation is an important parameter for the follow-up of Chronic Obstructive Pulmonary Disease (COPD) patients. Pulse oximeters are the most common non-invasive way to assess peripheral blood saturation. Invasive way for this is blood gas analyses. Smart watches are actually developed as sports and physical activity watches in order to be used in daily routine by assessing vital parameters such as heart rate, blood pressure and oxygen saturation. In this sense, they can help better monitoring for patients with COPD on the other hand accuracy of these devices is the major concern. Background: This study aims to evaluate the correlation of oxygen saturation assessed by smart watch, pulse oximetry and blood gas analyses in COPD patients. Methods: This is a cross-sectional study evaluating the pulse oximetry technology of smart watch by comparing it real time oxygen saturation measurements of conventional pulse device and arterial blood gas (ABG) analysis in 100 patients with COPD. Results: A moderate correlation was found between oxygen saturation levels obtained by smart watch, pulse oximetry and ABG. Conclusion: Smart watches are really smart. Thus, COPD patients can use smart watches to measure oxygen saturation levels in their daily lives. However, SpO2 measurements should be tested in other patient groups and also different degrees of COPD.
- 1 May 2025
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 20, 1457-1463
Open AccessAre Smart Watches Really Smart? Comparison of Blood Oxygen Saturation Values Measured by Smart Watch, Pulse Oximetry and Arterial Blood Gases in Patients with Chronic Obstructive Pulmonary Diseases
Objective: Oxygen saturation is an important parameter for the follow-up of Chronic Obstructive Pulmonary Disease (COPD) patients. Pulse oximeters are the most common non-invasive way to assess peripheral blood saturation. Invasive way for this is blood gas analyses. Smart watches are actually developed as sports and physical activity watches in order to be used in daily routine by assessing vital parameters such as heart rate, blood pressure and oxygen saturation. In this sense, they can help better monitoring for patients with COPD on the other hand accuracy of these devices is the major concern. Background: This study aims to evaluate the correlation of oxygen saturation assessed by smart watch, pulse oximetry and blood gas analyses in COPD patients. Methods: This is a cross-sectional study evaluating the pulse oximetry technology of smart watch by comparing it real time oxygen saturation measurements of conventional pulse device and arterial blood gas (ABG) analysis in 100 patients with COPD. Results: A moderate correlation was found between oxygen saturation levels obtained by smart watch, pulse oximetry and ABG. Conclusion: Smart watches are really smart. Thus, COPD patients can use smart watches to measure oxygen saturation levels in their daily lives. However, SpO2 measurements should be tested in other patient groups and also different degrees of COPD.